Disease manifestations and pathogenic mechanisms of group A Streptococcus

Walker, Mark J., Barnett, Timothy C., McArthur, Jason D., Cole, Jason N., Gillen, Christine M., Henningham, Anna, Sriprakash, K. S., Sanderson-Smith, Martina L. and Nizet, Victor (2014) Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clinical Microbiology Reviews, 27 2: 264-301. doi:10.1128/CMR.00101-13


Author Walker, Mark J.
Barnett, Timothy C.
McArthur, Jason D.
Cole, Jason N.
Gillen, Christine M.
Henningham, Anna
Sriprakash, K. S.
Sanderson-Smith, Martina L.
Nizet, Victor
Title Disease manifestations and pathogenic mechanisms of group A Streptococcus
Formatted title
Disease manifestations and pathogenic mechanisms of group A Streptococcus
Journal name Clinical Microbiology Reviews   Check publisher's open access policy
ISSN 0893-8512
1098-6618
Publication date 2014-01-01
Year available 2014
Sub-type Article (original research)
DOI 10.1128/CMR.00101-13
Open Access Status DOI
Volume 27
Issue 2
Start page 264
End page 301
Total pages 38
Place of publication Washington, DC, United States
Publisher American Society for Microbiology
Language eng
Subject 2713 Epidemiology
2400 Immunology and Microbiology
2739 Public Health, Environmental and Occupational Health
2726 Microbiology (medical)
2725 Infectious Diseases
Abstract Streptococcus pyogenes, also known as group A Streptococcus (GAS), causes mild human infections such as pharyngitis and impetigo and serious infections such as necrotizing fasciitis and streptococcal toxic shock syndrome. Furthermore, repeated GAS infections may trigger autoimmune diseases, including acute poststreptococcal glomerulonephritis, acute rheumatic fever, and rheumatic heart disease. Combined, these diseases account for over half a million deaths per year globally. Genomic and molecular analyses have now characterized a large number of GAS virulence determinants, many of which exhibit overlap and redundancy in the processes of adhesion and colonization, innate immune resistance, and the capacity to facilitate tissue barrier degradation and spread within the human host. This improved understanding of the contribution of individual virulence determinants to the disease process has led to the formulation of models of GAS disease progression, which may lead to better treatment and intervention strategies. While GAS remains sensitive to all penicillins and cephalosporins, rising resistance to other antibiotics used in disease treatment is an increasing worldwide concern. Several GAS vaccine formulations that elicit protective immunity in animal models have shown promise in nonhuman primate and early-stage human trials. The development of a safe and efficacious commercial human vaccine for the prophylaxis of GAS disease remains a high priority.
Formatted abstract
Streptococcus pyogenes, also known as group A Streptococcus (GAS), causes mild human infections such as pharyngitis and impetigo and serious infections such as necrotizing fasciitis and streptococcal toxic shock syndrome. Furthermore, repeated GAS infections may trigger autoimmune diseases, including acute poststreptococcal glomerulonephritis, acute rheumatic fever, and rheumatic heart disease. Combined, these diseases account for over half a million deaths per year globally. Genomic and molecular analyses have now characterized a large number of GAS virulence determinants, many of which exhibit overlap and redundancy in the processes of adhesion and colonization, innate immune resistance, and the capacity to facilitate tissue barrier degradation and spread within the human host. This improved understanding of the contribution of individual virulence determinants to the disease process has led to the formulation of models of GAS disease progression, which may lead to better treatment and intervention strategies. While GAS remains sensitive to all penicillins and cephalosporins, rising resistance to other antibiotics used in disease treatment is an increasing worldwide concern. Several GAS vaccine formulations that elicit protective immunity in animal models have shown promise in nonhuman primate and early-stage human trials. The development of a safe and efficacious commercial human vaccine for the prophylaxis of GAS disease remains a high priority.
Keyword Microbiology
Microbiology
MICROBIOLOGY
Q-Index Code C1
Q-Index Status Confirmed Code
Grant ID R01 AI077780
R01 AR052728
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Chemistry and Molecular Biosciences
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 131 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 152 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 15 May 2014, 21:29:30 EST by Christine Gillen on behalf of School of Chemistry & Molecular Biosciences